{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:12:44Z","timestamp":1793293964935,"version":"4.5.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EUSA Pharma Iberia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic multicentric Castleman disease (iMCD) is an infrequent and life-threatening disorder characterized by systemic inflammatory symptoms, generalized lymphadenopathy, polyclonal lymphocyte proliferation and organ dysfunction caused by a hyperinflammatory state. It accounts for one-third to one-half of all multicentric Castleman disease (MCD) cases. iMCD is often associated with autoimmune manifestations that may precede the iMCD diagnosis, be identified at the same time or follow it. In addition, iMCD may also coincide with a number of autoimmune diseases (such as psoriasis or myasthenia gravis) or autoinflammatory diseases (such as familial Mediterranean fever). Moreover, diverse inflammatory disorders, such as rheumatoid arthritis, systemic lupus erythematosus, adult-onset Still disease, systemic juvenile idiopathic arthritis, immunoglobulin (IgG4) related disease, or the recently described VEXAS syndrome, can present clinical features or lymphadenopathy with histopathological \u2018Castleman-like\u2019 findings compatible with those of iMCD. Given the iMCD clinical heterogeneity and the overlap with other autoimmune or autoinflammatory disorders, iMCD diagnosis can be challenging. In this review, we explore the overlap between iMCD and inflammatory diseases and provide practical guidance on iMCD diagnosis in order to avoid misdiagnosis and confusion with other autoimmune or autoinflammatory conditions.<\/jats:p>","DOI":"10.1093\/rheumatology\/keac481","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T09:29:23Z","timestamp":1661246963000},"page":"1426-1435","source":"Crossref","is-referenced-by-count":56,"title":["Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7367-9523","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Gonz\u00e1lez Garc\u00eda","sequence":"first","affiliation":[{"name":"Systemic Autoimmune and Orphan Diseases Unit, Department of Internal Medicine, Hospital Universitario Ram\u00f3n y Cajal, IRYCIS , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Fern\u00e1ndez-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital \u00c1lvaro Cunqueiro, University of Santiago de Compostela, Santiago de Compostela , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Robles Marhuenda","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Unit of the Internal Medicine Service, Hospital La Paz , Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8\u2013negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"339","DOI":"10.32074\/1591-951X-351","article-title":"Multicentric Castleman disease and the evolution of the concept","volume":"113","author":"Zhou","year":"2021","journal-title":"Pathologica"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s00432-020-03494-2","article-title":"Clinical characteristics and immunological abnormalities of Castleman disease complicated with autoimmune diseases","volume":"147","author":"Sun","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/BOR.0b013e32834db525","article-title":"Castleman disease and associated autoimmune disease","volume":"24","author":"Muskardin","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/keaa269","article-title":"Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene","volume":"60","author":"Endo","year":"2021","journal-title":"Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2008.10.005","article-title":"Multicentric Castleman\u2019s disease mimicking adult-onset Still\u2019s disease","volume":"76","author":"Bianchi","year":"2009","journal-title":"Joint Bone Spine"},{"key":"2023040420310230600_","first-page":"ECR03","article-title":"Systemic connective tissue disease complicated by Castleman\u2019s disease: report of a case and review of the literature","volume":"89","author":"De Marchi","year":"2004","journal-title":"Haematologica"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.25554","article-title":"Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?","volume":"94","author":"Fujimoto","year":"2019","journal-title":"Am J Hematol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.hoc.2017.09.005","article-title":"Diagnosis of castleman disease","volume":"32","author":"Szalat","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"81","DOI":"10.17305\/bjbms.2017.1930","article-title":"TAFRO syndrome: new subtype of idiopathic multicentric Castleman disease","volume":"17","author":"Srkalovic","year":"2017","journal-title":"Bosn J Basic Med Sci"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e163-175","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-101220-023458","article-title":"IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19","volume":"40","author":"Kishimoto","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/biology10040251","article-title":"A review of genetic abnormalities in unicentric and multicentric Castleman disease","volume":"10","author":"Butzmann","year":"2021","journal-title":"Biology"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e54610","DOI":"10.1371\/journal.pone.0054610","article-title":"Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels","volume":"8","author":"Stone","year":"2013","journal-title":"PloS One"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kep121","article-title":"The clinical spectrum of 94 patients carrying a single mutated MEFV allele","volume":"48","author":"Kon\u00e9-Paut","year":"2009","journal-title":"Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41379-021-00950-3","article-title":"Transcriptome and unique cytokine microenvironment of Castleman disease","volume":"35","author":"Wing","year":"2022","journal-title":"Mod Pathol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hoc.2017.09.009","article-title":"TAFRO Syndrome","volume":"32","author":"Igawa","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","article-title":"2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome","volume":"111","author":"Masaki","year":"2020","journal-title":"Int J Hematol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/tcmj.tcmj_15_20","article-title":"Updates on the diagnosis and management of multicentric Castleman disease","volume":"33","author":"Wu","year":"2021","journal-title":"Tzu-Chi Med J"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"678927","DOI":"10.3389\/fimmu.2021.678927","article-title":"Case report: VEXAS syndrome: from mild symptoms to life-threatening macrophage activation syndrome","volume":"12","author":"Staels","year":"2021","journal-title":"Front Immunol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.2169\/internalmedicine.2989-19","article-title":"Idiopathic multicentric castleman disease with autoimmune hemolytic anemia and production of anti-drug antibody against tocilizumab","volume":"58","author":"Tabata","year":"2019","journal-title":"Intern Med"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/hon.2969","article-title":"Bone marrow findings of idiopathic Multicentric Castleman disease: a histopathologic analysis and systematic literature review","volume":"40","author":"Belyaeva","year":"2022","journal-title":"Hematol Oncol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ekir.2020.05.004","article-title":"The clinical and histopathological feature of renal manifestation of TAFRO syndrome","volume":"5","author":"Mizuno","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e1608","DOI":"10.1542\/peds.2010-1123","article-title":"Iron-deficiency anemia in castleman disease: implication of the interleukin 6\/hepcidin pathway","volume":"126","author":"Arlet","year":"2010","journal-title":"Pediatrics"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-il6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"21","author":"Casper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10157-011-0499-9","article-title":"Renal complications of Castleman\u2019s disease: report of two cases and analysis of 75 cases","volume":"15","author":"Yuan","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfq427","article-title":"Renal involvement in Castleman disease","volume":"26","author":"El Karoui","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"iii119","DOI":"10.1093\/ndt\/gfr245","article-title":"Renal involvement in a large cohort of Chinese patients with Castleman disease","volume":"27","author":"Xu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e234155","DOI":"10.1136\/bcr-2019-234155","article-title":"Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology","volume":"13","author":"Simeni Njonnou","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.3390\/ijms22126286","article-title":"TAFRO syndrome with renal thrombotic microangiopathy: insights into the molecular mechanism and treatment opportunities","volume":"22","author":"Tu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01489","article-title":"Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review","volume":"10","author":"Leurs","year":"2019","journal-title":"Front Immunol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13730-019-00400-9","article-title":"Pathological findings of progressive renal involvement in a patient with TAFRO syndrome","volume":"8","author":"Saito","year":"2019","journal-title":"CEN Case Rep"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1590\/abd1806-4841.20199165","article-title":"Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview","volume":"94","author":"Maruta","year":"2019","journal-title":"An Bras Dermatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/ajcp\/aqaa053","article-title":"Predominant stroma-rich feature in hyaline vascular variant of castleman disease is associated with paraneoplastic pemphigus","volume":"154","author":"Wang","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/1756-185X.13407","article-title":"Masked pemphigus among pediatric patients with Castleman\u2019s disease","volume":"22","author":"Han","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2340\/00015555-3253","article-title":"Cutaneous disorders associated with Castleman\u2019s disease","volume":"99","author":"Kim","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1503\/cmaj.081504","article-title":"Clinical images: Castleman disease and paraneoplastic pemphigus","volume":"182","author":"Kop","year":"2010","journal-title":"CMAJ"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/bjd.14162","article-title":"Clinical and immunological findings in 104 cases of paraneoplastic pemphigus","volume":"173","author":"Ohzono","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"808536","DOI":"10.3389\/fmolb.2021.808536","article-title":"Autoimmune Pemphigus: latest advances and emerging therapies","volume":"8","author":"Lim","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e352\u20134","DOI":"10.1111\/ijd.15528","article-title":"Successful use of intravenous and intralesional rituximab in paraneoplastic pemphigus with Castleman\u2019s disease","volume":"60","author":"Viswanath","year":"2021","journal-title":"Int J Dermatol"},{"key":"2023040420310230600_","first-page":"e5022","article-title":"Paraneoplastic pemphigus with underlying Castleman\u2019s disorder: a rare report with literature review","volume":"11","author":"Bin Waqar","year":"2019","journal-title":"Cureus"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.hoc.2017.09.004","article-title":"Pathology of Castleman disease","volume":"32","author":"Wu","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s100670050143","article-title":"Localised hyaline vascular type of Castleman\u2019s disease mimicking adult-onset Still\u2019s disease","volume":"18","author":"Lin","year":"1999","journal-title":"Clin Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s10067-003-0797-z","article-title":"Systemic juvenile idiopathic arthritis mimics multicentric Castleman\u2019s disease","volume":"22","author":"Osone","year":"2003","journal-title":"Clin Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/biores.2017.0025","article-title":"Possible association of multicentric Castleman\u2019s disease with autoimmune lymphoproliferative syndrome","volume":"7","author":"Minemura","year":"2018","journal-title":"BioRes Open Access"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00296-020-04684-4","article-title":"Systemic lupus erythematosus complicated with Castleman disease: a case-based review","volume":"41","author":"Demirkan","year":"2021","journal-title":"Rheumatol Int"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jbspin.2018.10.007","article-title":"Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers)","volume":"86","author":"Chasset","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e12291","DOI":"10.1097\/MD.0000000000012291","article-title":"Castleman disease mimicking systemic lupus erythematosus: a case report","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1440-1827.2000.01052.x","article-title":"Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases","volume":"50","author":"Kojima","year":"2000","journal-title":"Pathol Int"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.prp.2007.03.002","article-title":"Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients","volume":"203","author":"Kojima","year":"2007","journal-title":"Pathol Res Pract"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopha.2006.09.004","article-title":"Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients","volume":"60","author":"Kojima","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset Still\u2019s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2023040420310230600_","first-page":"roab115","article-title":"Performance of recent PRINTO criteria versus current ILAR criteria for systemic juvenile idiopathic arthritis: a single-centre experience","author":"Koker","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1182\/blood-2010-04-280347","article-title":"Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop","volume":"116","author":"Oliveira","year":"2010","journal-title":"Blood"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ajh.25495","article-title":"POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Dispenzieri","year":"2019","journal-title":"Am J Hematol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/ejh.13514","article-title":"POEMS syndrome: a multisystem clonal disorder","volume":"106","author":"Ali","year":"2021","journal-title":"Eur J Haematol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejrad.2009.06.004","article-title":"18F-FDG PET\/CT in the evaluation of POEMS syndrome","volume":"76","author":"Albert\u00ed","year":"2010","journal-title":"Eur J Radiol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"212","DOI":"10.18176\/jiaci.0633","article-title":"Immunoglobulin G4\u2013related disease: what an allergist should know","volume":"31","author":"Carballo","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2018.205526","article-title":"IgG4-related disease: what a hematologist needs to know","volume":"104","author":"Chen","year":"2019","journal-title":"Haematologica"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/keab634","article-title":"Immunoglobulin G4\u2013related disease and idiopathic multicentric Castleman\u2019s disease: confusable immune-mediated disorders","volume":"61","author":"Sasaki","year":"2022","journal-title":"Rheumatology"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.semdp.2017.11.006","article-title":"Lymphadenopathy associated with IgG4-related disease: diagnosis & differential diagnosis","volume":"35","author":"Wick","year":"2018","journal-title":"Semin Diagn Pathol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.18632\/oncotarget.24068","article-title":"Idiopathic multicentric Castleman\u2019s disease: a clinicopathologic study in comparison with IgG4-related disease","volume":"9","author":"Otani","year":"2018","journal-title":"Oncotarget"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14397595.2018.1548089","article-title":"IgG4-related respiratory disease","volume":"29","author":"Matsui","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/pin.13185","article-title":"Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease","volume":"72","author":"Nishikori","year":"2022","journal-title":"Pathol Int"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1097\/RHU.0000000000001787","article-title":"IgG4-related disease: mimickers and diagnostic pitfalls","volume":"28","author":"Mart\u00edn-Nares","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/modpathol.2009.17","article-title":"Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman\u2019s disease","volume":"22","author":"Sato","year":"2009","journal-title":"Mod Pathol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-017-1231-2","article-title":"Circulating plasmablasts\/plasma cells: a potential biomarker for IgG4-related disease","volume":"19","author":"Lin","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/pin.12932","article-title":"Clinicopathological differential diagnosis of IgG4-related disease: a historical overview and a proposal of the criteria for excluding mimickers of IgG4-related disease","volume":"70","author":"Satou","year":"2020","journal-title":"Pathol Int"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"2023040420310230600_","first-page":"3591","article-title":"VEXAS syndrome","volume":"137","author":"Grayson","year":"2021","journal-title":"Blood"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-021-00217-2","article-title":"VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder","volume":"10","author":"Huang","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"2023040420310230600_","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.seminhematol.2021.10.007","article-title":"Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome","volume":"58","author":"Patel","year":"2021","journal-title":"Semin Hematol"},{"key":"2023040420310230600_","article-title":"VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist","author":"Sterling","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac481\/47428256\/keac481.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/4\/1426\/49750294\/keac481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/4\/1426\/49750294\/keac481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T21:51:14Z","timestamp":1700949074000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/4\/1426\/6673927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,23]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac481","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2022,8,23]]}}}